Endothelial dysfunction increases cardiovascular disease risk in chronic kidney disease (CKD). This study investigates whether VDR activation affects endothelial function in CKD. The 5/6 nephrectomized (NX) rats with experimental chronic renal insufficiency were treated with or without paricalcitol, a VDR activator. Thoracic aortic rings were precontracted with phenylephrine and then treated with acetylcholine or sodium nitroprusside. Uremia significantly affected aortic relaxation (-50.0±7.4% in NX rats versus -96.2±5.3% in SHAM at 30 μM acetylcholine). The endothelial-dependent relaxation was improved to -58.2±6.0% , -77.5±7.3% , and -90.5±4.0% in NX rats treated with paricalcitol at 0.021, 0.042, and 0.083 μg/kg for two weeks, respectively, while paricalcitol at 0.042 μg/kg did not affect blood pressure and heart rate. Parathyroid hormone (PTH) suppression alone did not improve endothelial function since cinacalcet suppressed PTH without affecting endothelial-dependent vasorelaxation. N-omega-nitro-L-arginine methyl ester completely abolished the effect of paricalcitol on improving endothelial function. These results demonstrate that VDR activation improves endothelial function in CKD. © 2010 J. RuthWu-Wong et al.
Wu-Wong, J. R., Noonan, W., Nakane, M., Brooks, K. A., Segreti, J. A., Polakowski, J. S., & Cox, B. (2010). Vitamin D receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats. International Journal of Endocrinology, 2010. https://doi.org/10.1155/2010/625852